Description
Seeking men and women with advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes for a study comparing targeted drug combinations
Overview
Participants in this study will be assigned to get either chemotherapy with INC280 (capmatinib) and osimertinib pills or INC280 (capmatinib), osimertinib pills and ramucirumab infusion. Following chemotherapy treatments there will be follow-up visits every 3 to 6 months for up to 3 years. Chemotherapy will be given on 28-day cycles with ramucirumab infusions on day 1 and 15 of the cycle.
What we're hoping for
We are comparing two targeted drug combinations for advanced Non-Small Cell Lung Cancer that has EGFR and MET Gene Changes
Additional Information
ClinicalTrials.gov Identifier: NCT05642572